Appendix Table 3.

Therapeutic Classes for Initial Use Patients Initiated on a Fixed-Dose or Free-Equivalent Combination

Therapeutic class*	FDC* (n=795)	FEC* (n=712)
ACEI & Thiazide, n (%)	397 (49.9)	187 (26.3)
ARB & Thiazide, n (%)	250 (31.5)	39 (5.5)
ACEI & CCB, n (%)	83 (10.4)	80 (11.2)
ACEI & β-blocker, n (%)	0 (0)	140 (19.7)
β-blocker & Thiazide, n (%)	34 (4.3)	81 (11.4)
CCB & Thiazide, n (%)	0 (0)	73 (10.3)
ARB & CCB, n (%)	31 (3.9)	28 (3.9)
β-blocker & CCB, n (%)	0 (0)	38 (5.3)
ARB & β-blocker, n (%)	0 (0)	34 (4.8)
ACEI & ARB, n (%)	0 (0)	12 (1.7)

^*Abbrev: FDC, fixed-dose combinations; FEC, free-equivalent combinations; ACEI, angiotensin-converting-enzyme inhibitor; Thiazide, thiazide and thiazide-like diuretics; β-blocker, beta blockers cardio-selective; ARB, angiotensin II receptor antagonist; CCB, calcium channel blockers.